Reuters logo
BRIEF-Horizon Pharma presents data analyses demonstrating clinical benefit of Krystexxa
2017年6月14日 / 下午2点03分 / 4 个月前

BRIEF-Horizon Pharma presents data analyses demonstrating clinical benefit of Krystexxa

June 14 (Reuters) - Horizon Pharma Plc

* Horizon Pharma Plc presents new data analyses further demonstrating clinical benefit of Krystexxa® (pegloticase) in patients with uncontrolled gout

* Horizon Pharma Plc says study compared 62 patients who had clinically apparent tophi at baseline and 23 patients who did not

* Horizon Pharma Plc says both groups had significant clinical benefit over six months of treatment with krystexxa Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below